Portal de Periódicos da CAPES

Caracterización de la enfermedad inflamatoria intestinal en Colombia: resultados de un registro nacional

2020; Elsevier BV; Volume: 86; Issue: 2 Linguagem: Inglês

10.1016/j.rgmx.2020.05.005

2255-5528

Fabián Juliao Baños, F. Puentes, Rocío López, María A. Saffon, Gonzalo David Ross Reyes, Viviana Parra, M.T. Galiano, M. Barraza, Jenny Molano, E. Álvarez, Rosa M. Corrales, L Vargas, F. Gil, Patricia Álvarez, L. Limas, Rubén Rúa Prieto, Paola Yance, F. Díaz, José Bareño Silva, Fabián Juliao Baños, Mateo Arrubla, Joselyn Camargo, Fabián Puentes, Lázaro Antonio Arango Molano, Rocío López, Rafael García Pavón, Belén Mendoza, María A. Saffon, Luis F. Roldán, Julio Zuleta, Gustavo Reyes, Viviana Parra, Cristian Flórez, Edilberto Núñez, M.T. Galiano, Marcos Barraza, Isabel C. Sanchez, Jenny Molano, Jorge Iván Lizarazo, Iván Cuellar, Eligio Álvarez, Rosa M. Corrales, Fabio Gil, L Vargas, Patricia Álvarez, Luis Manuel Limas, Robín Germán Prieto, Hernán Ballén, Lidsay Delgado, Paola Yance, Felha Díaz,

Eosinophilic Esophagitis

Determinar las características clínicas, sociodemográficas y tratamiento de la EII en un registro de la población colombiana. Estudio observacional descriptivo, analítico, multicéntrico, de corte transversal de una cohorte nacional de pacientes con EII en 17 centros de nueve ciudades del país. Se documentaron 2,291 pacientes con EII, 1,813 (79.1%) con CU, 456 (19.9%) con EC y 22 con EII no clasificable (0.9%). La razón CU/EC es de 3.9:1. 18.5% de los pacientes con CU y 47.3% con EC han recibido terapia biológica. Los pacientes con CU extensa presentaban mayor uso de terapia biológica (OR = 2.78; IC 95%: 2.10-3.65; P = 0.000), mayor tasa de cirugía (OR = 5.4; IC 95%: 3.5-8.3; P = 0.000) y mayor frecuencia de hospitalización (OR = 4.34; IC 95%: 3.47-5.44; P = 0.000). Los pacientes con CU severa presentaban mayor uso de terapia biológica (OR = 5.04; IC 95%: 3.75-6.78; P = 0.000), mayor tasa de cirugía (OR = 8.64; IC 95%: 5.4-13.78; P = 0.000) y mayor frecuencia de hospitalización (OR = 28.45; IC 95%: 19.9-40.7; P = 0.000). Los pacientes con EC inflamatorio (B1) presentaban menor frecuencia de hospitalización (OR = 0.12; IC 95%: 0.07-0.19; P = 0.000), menor tasa de cirugía (OR = 0.08; IC 95%: 0.043-0.15; P: 0.000) y menor uso de terapia biológica (OR = 0.26; IC 95%: 0.17-0.41; P: 0.000). En nuestro país existe un predominio de CU sobre EC (3.9:1), como ocurre en otros países de Latinoamérica. Los pacientes con CU extensa y severa y con EC de comportamiento no inflamatorio (B2, B3) tienen peor pronóstico. To determine the clinical, sociodemographic, and treatment characteristics of inflammatory bowel disease (IBD) in a Colombian population register. A descriptive, analytic, observational, cross-sectional, multicenter study on patients with IBD from 17 hospital centers in 9 Colombian cities was conducted. A total of 2,291 patients with IBD were documented, 1,813 (79.1%) of whom presented with ulcerative colitis (UC), 456 (19.9%) with Crohn's disease (CD), and 22 with IBD unclassified (0.9%). The UC/CD ratio was 3.9:1. A total of 18.5% of the patients with UC and 47.3% with CD received biologic therapy. Patients with extensive UC had greater biologic therapy use (OR = 2.78, 95% CI: 2.10-3.65, p = 0.000), a higher surgery rate (OR = 5.4, 95% CI: 3.5-8.3, p = 0.000), and greater frequency of hospitalization (OR = 4.34, 95% CI: 3.47-5.44, p = 0.000). Patients with severe UC had greater biologic therapy use (OR = 5.04, 95% CI: 3.75-6.78, p = 0.000), a higher surgery rate (OR = 8.64, 95% CI: 5.4-13.78, p = 0.000), and greater frequency of hospitalization (OR = 28.45, 95% CI: 19.9-40.7, p = 0.000). CD patients with inflammatory disease behavior (B1) presented with a lower frequency of hospitalization (OR = 0.12, 95% CI: 0.07-0.19, p = 0.000), a lower surgery rate (OR = 0.08, 95% CI: 0.043-0.15, p = 0.000), and less biologic therapy use (OR = 0.26, 95% CI: 0.17-0.41, p = 0.000). In Colombia, there is a predominance of UC over CD (3.9:1), as occurs in other Latin American countries. Patients with extensive UC, severe UC, or CD with noninflammatory disease behavior (B2, B3) have a worse prognosis.